Physician profile
Mark D Hamilton
NPI 1003939737
$653.39
in general payments reported to CMS, 2019-2025
16 companies · $380 in 2025
The $380 reported for 2025 was more than what 89% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.29 · 2023: $54.66 · 2024: $207 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103.38 | 2025 | |
| Ardelyx, INC. | $100.56 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $68.31 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $64.85 | 2023-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.14 | 2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $48.91 | 2024-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $44.50 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $26.90 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $24.53 | 2024 | Bylvay |
| Novo Nordisk INC | $21.65 | 2025 | Wegovy |
| Celltrion USA INC. | $20.99 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $18.35 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $17.05 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $15.85 | 2024 | Idacio |
| Qol Medical, LLC | $15.13 | 2024 | Sucraid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.